MODIFIED VACCINIA VIRUS ANKARA-5T4 ANTIGEN
Clear Cell Renal Carcinoma
Oxford BioMedicavaccinePhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 46/ 100
- Competitive Position
- 89/ 100
Competitive context
24 Active assets in the Clear Cell Renal Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Everolimus Peking University First Hospital | Phase 2 | BB |
Axitinib University of California, San Francisco | Phase 3 | B |
Nivolumab Exelixis | Phase 2 | B |
gw786034 Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | Phase 2 | B |
Belzutifan José Claudio Casali da Rocha | Phase 2 | B |
View all 39 →
Same molecule, other indications
MODIFIED VACCINIA VIRUS ANKARA-5T4 ANTIGEN is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →